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Edited by Ivan SadowskiAbstract TRIM11 is a member of the tripartite-motif-contain-
ing protein family and is known to destabilize humanin, an inhib-
itor of Alzheimer-like neuronal insults. In this study, we
demonstrate that TRIM11 interacts with activator-recruited
cofactor 105-kDa component (ARC105) that mediates chroma-
tin-directed transcription activation and is a key regulatory
factor for transforming growth factor b (TGFb) signaling. Co-
expression of TRIM11 increased ARC105 degradation but a
proteasome inhibitor suppressed this. Co-expression of TRIM11
and ARC105 also increased ubiquitination of ARC105. In addi-
tion, TRIM11 suppressed ARC105-mediated transcriptional
activation induced with TGFb in a reporter assay. These results
suggest that TRIM11, with the ubiquitin–proteasome pathway,
regulates ARC105 function in TGFb signaling.
 2006 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
Keywords: TRIM/RBCC; Ubiquitin-proteasome system;
Transcription mediator; TGFb1. Introduction
The tripartite motif-containing (TRIM) family is a subgroup
of the really interesting new gene (RING) ﬁnger-containing
protein family. TRIM proteins contain a RING ﬁnger, a B-
box, and a coiled-coil domain, making them members of the
RING B-box coiled-coil (RBCC) protein family as well. The
TRIM proteins, promyelocytic leukemia protein (PML,
TRIM19), ret ﬁnger protein (RFP, TRIM27), and transcrip-
tion intermediary factor 1 (Tif1, TRIM24) have been well-
studied and shown to be oncogenic when fused by chromo-
somal translocation to retinoic acid receptor a (RARa),Abbreviations: TRIM, tripartite motif-containing protein; RBCC, R-
ING B-box coiled-coil; RING, really interesting new gene; ARC105,
activator recruited cofactor 105-kDa component; GFP, green ﬂuores-
cent protein; HEK293, human embryonic kidney 293 cells; Ub, ubiq-
uitin; E2s, ubiquitin conjugating enzymes; TGFb, transforming growth
factor b; MALDI-TOF/MS, matrix assisted laser desorption/ioniza-
tion time of ﬂight mass spectrometry; PMSF, phenylmethylsulfonyl
ﬂuoride; PMF, peptide mass ﬁngerprint; CMV, cyto megalo virus
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doi:10.1016/j.febslet.2006.07.066RET, or B-raf, respectively [1–3]. Some of the TRIM family
members form homo- and/or heterooligomers and function
in multi-protein complexes [4].
TRIM11 (with 468 amino acid residues) is a typical RBCC
protein and forms homooligomers [5]. A green ﬂuorescent pro-
tein (GFP)-TRIM11 fusion protein localizes to both the cyto-
plasm and nucleus in mammalian cells (http://www.tigem.it/
TRIM/). TRIM11 also interacts with humanin, a neuroprotec-
tive peptide that speciﬁcally suppresses Alzheimer’s disease-re-
lated neurotoxicity, and TRIM11 is proposed to help regulate
intracellular levels of humanin through ubiquitin-mediated pro-
tein degradation in neural tissues [6]. Humanin interacts with
apoptotic factor Bax and induces antiapoptotic eﬀects by inhib-
iting translocation of Bax to the mitochondria [7]; thus,
TRIM11 may regulate apoptosis by controlling humanin
stability. TRIM11 mRNA is ubiquitously expressed in adult
mouse tissues, including the thymus, testis, spleen, and liver,
and is highly expressed in embryonic kidney and nerve systems
(http://www.tigem.it/TRIM/); however, the function of
TRIM11 remains explored.
In this study, we identiﬁed potential TRIM11-interacting
proteins using a combination of pull-down assays and mass-
spectrometry-based analysis and found that activator-recruited
cofactor 105-kDa component (ARC105) is a novel TRIM11-
interacting protein. We also showed evidence that ARC105-
mediated transcriptional activation induced by transforming
growth factor b (TGFb) signaling is regulated by TRIM11
through an ubiquitin-mediated degradation pathway.2. Materials and methods
2.1. Materials
Anti-FLAG-M2, anti-HA, anti-b-tubulin, anti-GFP and anti-mouse
IgG Cy3-conjugated antibody was obtained from Sigma–Aldrich (To-
kyo, Japan). Anti-GAPDH antibody was obtained from Ambion (Aus-
tin, TX, USA). Anti-Myc rabbit polyclonal antibody was purchased
from BioVision Research Products (Mountain View, CA, USA).
Anti-mouse IgG and anti-rabbit IgG alkaline phosphatase-conjugated
antibody was obtained from Cell Signaling Technology (Beverly, MA,
USA). MG132 was obtained from Calbiochem (La Jolla, CA, USA).
Human recombinant TGF-b1 was obtained fromNakalai Tesque (Kyo-
to, Japan). p3TP-Lux vector was kindly provided by Dr. Miyazono.
2.2. Cloning and construction for FLAG-tagged, HA-tagged, and
Myc-tagged fusion proteins
RT-PCR was performed using the Super Script II kit (Invitrogen,
Carlsbad, CA, USA) according to the manufacturer’s protocol usingblished by Elsevier B.V. All rights reserved.
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293EBNA cells (Invitrogen). cDNA for C-terminally FLAG-tagged
TRIM11 (TRIM11-FLAG) (GenBank Accession: AF327056) and
FLAG-tagged ARC105 (ARC105-FLAG) (GenBank Accession:
BC013985) were obtained by PCR with the following primer sets; 5 0-
GAAGAAAAGCTTCACCATGGGAGCCGCCCCCGACCTGTC-
CACC-3 0 and 5 0-CAAGAATTCTTACTTATCGTCGTCATCCTTG-
TAATCGGCACCAGAACCCTGGGGAGCCAGGGTGTCCCC-3 0
for TRIM11, and 5 0-GAAGAAGGATCCCACCATGGACGTTTC-
CGGGCAAGAG-3 0 and 5 0-CAAGAATTCTTACTTATCGTCGT-
CATCCTTGTAATCGGCACCAGAACCGGCGGCTGAGAGGC-
AGGCCTG-3 0 for ARC105. The PCR product was cloned into the
HindIII/EcoRI sites of the expression vector pcDNA3.1(+) for
TRIM11 and into the BamHI/EcoRI sites for ARC105. Using the
cloned FLAG-tagged TRIM11 as template, TRIM11 lacking the
FLAG tag was ampliﬁed by PCR with a primer set, 5 0-
GAAGAAAAGCTTCACCATGGGAGCCGCCCCCGACCTGTC-
CACC-3 0 and 5 0-CAAGAATTCCCTGGGGAGCCAGGGTGTCC-
CC-3 0. The PCR product was then ligated into the HindIII and EcoRI
sites of the pEGFP-N1 vector (Invitrogen) to generate GFP-tagged
TRIM11 (TRIM11-GFP). Using the cloned FLAG-tagged ARC105
as template, HA-tagged ARC105 was ampliﬁed by PCR with the pri-
mer set, 5 0-GAAGAAGGATCCCACCATGGACGTTTCCGGGCA-
AGAG-30 and 5 0-CAAGAATTCTTAGGCGTAGTCCGGGACGT-
CATATGGGTAGGCACCAGAACCGGCGGCTGAGAGGCAG-
GCCTG-3 0. The PCR product was then ligated into the BamHI and
EcoRI sites of the pcDNA3.1(+) vector to generate ARC105-HA.
Myc-tagged TRIM11 (TRIM11-Myc) was obtained by PCR ampliﬁca-
tion of the cloned FLAG-tagged TRIM11 and a set of primers; 5 0-
GAAGAAAAGCTTCACCATGGGAGCCGCCCCCGACCTGTCC-
ACC-3 0 and 50-CAAGAATTCTTACAAGTCCTCTTCAGAAAT-
GAGCTTTTGCTCGGCACCAGAACCCTGGGGAGCCAGGGT-
GTCCCC-30. Ampliﬁed product was ligated into the HindIII and
EcoRI sites of the pcDNA3.1(+) vector. All constructs were veriﬁed
by DNA sequence analysis.
2.3. Construction of TRIM11 deletion mutants
The domain structure of TRIM11 was analyzed with Pfam (http://
www.sanger.ac.uk/Software/Pfam/) and Smart (http://smart.emblhei-
delberg.de/smart/) Sequence Analyzing Tools. A coiled-coil-speciﬁc
analyzing tool (http://www.ch.embnet.org/software/COILS_-
form.html) was used to determine the location of the coiled-coil region.
The expression plasmids for TRIM11-FLAG deletion mutants were
constructed using PCR with pcDNA3.1(+)-TRIM11-FLAG as tem-
plate. DNA fragments for the TDN deletion series were ampliﬁed by
PCR with a combination of the TRIM11 reverse cloning primer de-
scribed above and the forward primer; 5 0-GAAGAAAAGCTTCAC-
CATGGTCCCGCAGGGCGTGTGCCC-3 0 for TDN-R, 5 0-GAAG-
AAAAGCTTCACCATGGGACTGCAGGACGCGGCCGAAGAC-
3 0 for TDN-RB, or 5 0-GAAGAAAAGCTTCACCATGGGACG-
AGGGGACGTGACCTTGGAC-3 0 for TDN-RBCC. The ampliﬁed
DNA fragments were ligated into the HindIII and EcoRI sites of
pcDNA3.1(+).
DNA fragments for the TDC deletion series were ampliﬁed by PCR
with a combination of the forward primer 5 0-GAAGGTACC-
GGTGCCGATTACAAGGATGACGACGAT-3 0 and the reverse
primers 50-GAAGGTACCGGTGAAGCGCTCCTGGCCCAG-30 for
TDC-SP, 50-GAAGGTACCAAACCTCCGCAGTGTCTCTAC-30 for
TDC-SASP, and 5 0-GAAGGTACCCAGCGGCCGCACGCGGTG-
CG-30 for TDC-CCSASP. The ampliﬁed fragments were digested with
KpnI and self-ligated.
For the construction of Myc-tagged TDN-R or TDN-RB deletion
mutants, the DNA fragment encoding the N-terminal region of
TRIM11 was removed by cleavage at the HindIII and BamHI site of
the pcDNA3.1(+) plasmid containing the Myc-tagged TRIM11, and
the plasmid was ligated to the DNA fragment encoding the N-terminal
region of TDN-R or TDN-RB that had been cleaved from the FLAG-
tagged TDN-R or TDN-RB pcDNA3.1(+) plasmid at the HindIII and
BamHI site.
2.4. Cell culture and transfection
Human embryonic kidney 293 (HEK293) cells and HEK293 cells
that express the Epstein-Barr virus nuclear antigen (293EBNA) were
maintained according to standard methods in Dulbecco’s modiﬁed Ea-
gle’s medium (Nissui Pharmaceuticals, Tokyo, Japan) supplementedwith 10% heat-inactivated fetal calf serum in a humidiﬁed atmosphere
of 95% air and 5% CO2 [8]. Transfection was performed by either the
calcium phosphate method or using LipofectAMINE (Invitrogen) [8].
2.5. Pull-down analysis
Cells were harvested at 48 h after transfection, washed twice with ice-
cold PBS, and centrifuged at 1500 rpm for 5 min at 4 C. Cell pellets
were resuspended in lysis buﬀer (50 mM Tris–HCl, pH 8.0, 150 mM
NaCl, containing 0.5% IGEPAL-CA630, protease inhibitors; 0.1 mM
phenylmethylsulfonyl ﬂuoride (PMSF), 2 lg/ml aprotinin, 2 lg/ml leu-
peptin and 2 lg/ml pepstatin) and incubated on ice for 30 min. Cell deb-
ris was removed by centrifugation at 15000 rpm for 30 min at 4 C.
Anti-FLAG-M2-conjugated agarose beads (Sigma–Aldrich, Tokyo,
Japan) were added to the cleared lysate, and the mixture was rotated
for 4–6 h at 4 C. The anti-FLAG-M2 agarose beads were collected,
washed ﬁve times with lysis buﬀer and once with detergent-free lysis buf-
fer, and then bound proteins were eluted with 500 lg/ml FLAGpeptide.
2.6. SDS–PAGE and Western blotting
SDS–PAGE gels were subjected to Western blotting after electro-
transfer to PVDF membranes according to methods described previ-
ously [8]. The membranes were blocked with 5% non-fat dried skim
milk in TBST (50 mM Tris–HCl, pH 7.4, 0.1% (w/v) Tween 20,
150 mM NaCl) for 30 min, and incubated with the appropriate pri-
mary antibody for 1 h. The membranes were rinsed three times with
TBST for 10 min, incubated with secondary antibody conjugated with
alkaline phosphatase for 1 h and washed four times with TBST. Stain-
ing was performed in NBT/BCIP solution, prepared by a (1:50) dilu-
tion of NBT/BCIP stock solution (Roche, Diagnostics, Manheim,
Germany) with alkaline phosphatase buﬀer (100 mM Tris–HCl, pH
9.5, 100 mM NaCl, and 50 mM MgCl2).
2.7. Matrix assisted laser desorption/ionization time of ﬂight mass
spectrometry (MALDI-TOF/MS) and peptide mass ﬁngerprint
(PMF) analysis
Each of protein staining bands on an SDS–PAGE gel was excised
and subjected to in-gel protease digestion as described previously [9].
The peptides generated were recovered with ZipChip and analyzed
by the PMF method using a PE Biosystems MALDI-TOF mass spec-
trometer (Voyager DE-STR, PE Biosystems, Foster City, CA). Using
50 ppm mass accuracy, the peptide masses were compared to the NCBI
nr database using the database ﬁtting program MS-Fit (http://prospec-
tor.ucsf.edu/ucsfhtml4.0/msﬁt.htm), and protein identiﬁcation was car-
ried out using criteria described previously [8].
2.8. Immunocytochemistry
Human 293EBNA cells were cultured on collagen-coated culture
glass slides (Biocoat, Becton Dickinson Labware) and transfected with
expression plasmid DNA using LipofectAMINE. The transfected and
intact cells were ﬁxed with 3.7% formaldehyde in PBS. After washing
with PBST (PBS containing 0.05% (w/v) Tween 20), the cells were per-
meabilized with 0.1% (w/v) Triton X-100 for 5 min, and treated with
3% non-fat dried skim milk in PBS at room temperature for 30 min.
The cells were then incubated with the appropriate primary antibody
for 1 h at room temperature. After a wash with PBST, the cells were
further incubated with ﬂuorochrome-conjugated secondary antibody
for 1 h at room temperature. After incubation, the slides were washed
and mounted with Vectashield (Vector Laboratories, Burlingame, CA,
USA). Fluorescence images were visualized with an Axiovert 200 M
microscope (Carl Zeiss, Germany). Exogenously expressed FLAG-
tagged ARC105 was visualized with anti-FLAG-M2 (1:500) and
anti-mouse IgG conjugate Cy3 antibody (1:1000). Native ARC105
was visualized with anti-ARC105 (PAQ6C9, 1:50) and anti-mouse
IgG conjugate Cy3 antibody (1:1000).
2.9. Establishment of cell lines for stable expression of ARC105
HEK293 cells were transfected with ScaI-linearized pcDNA3.1(+)-
ARC105-HA plasmid to establish strains with stable expression of the
HA-tagged ARC105 fusion protein. The transfected cells were selected
for at least two weeks with 500 lg/ml G418 (Gibco, Grand Island, NY,
USA). The resulting G418-resistant cells were seeded on 96-well plates
and incubated for at least one week for secondary clone selection. Iso-
lated colonies were propagated in 24-well plates and the protein expres-
sion level of ARC105-HA was monitored by Western blotting.
Fig. 1. Association of TRIM11 with ARC105. (A) SDS–PAGE of
TRIM11-FLAG-associated proteins. Pull-down analysis of TRIM11-
FLAG in transfected cells. Protein bands were detected by silver
staining. The protein bands identiﬁed by MS analysis after in-gel
protease digestion are indicated. An asterisk indicates a protein band
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Three expression vectors, pcDNA3.1(+)-ARC105-HA,
pcDNA3.1(+)-TRIM11-FLAG, and pEGFP-N1-GFP, were mixed in
a ratio of 8:1:1 and transfected into 293EBNA cells. After 24 h cultiva-
tion, the transfected cells were incubated further with or without
10 lM MG132 for 12 h. Whole-cell extract (100 lg) was subjected to
Western blot analysis with anti-FLAG, anti-HA, anti-tubulin, and
anti-GFP antibodies as described above (SDS–PAGE and Western
blotting). As a control or antagonistic experiment, pcDNA3.1(+)-
empty vector or pcDNA3.1(+)-TDN-R-FLAG was used, respectively,
in place of pcDNA3.1(+)-TRIM11-FLAG. For analysis of the dose-
dependent eﬀect of TRIM11 on ARC105 stabilization, a mixture of
pcDNA3.1(+)-empty vector and pcDNA3.1(+)-TRIM11-FLAG in a
ratio of 1:0, 3:1, 1:1 or 0:1 was transfected with pcDNA3.1(+)-
ARC105-HA and pEGFP-N1-GFP into 293EBNA cells. The total
amount of vector in each experiment was adjusted to 0.625 lg. For
the eﬀect of the TRIM11 domain mutant on the stabilization of
ARC105, pcDNA3.1(+)-TDN-R-FLAG was used instead of
pcDNA3.1(+)-TRIM11-FLAG.
2.11. In vivo ubiquitination assay
A mixture of expression vectors, pCGN-HA-Ub (0.375 lg),
pcDNA3.1(+)-ARC105-FLAG (0.75 lg) and, pcDNA3.1(+)-empty
vector (0.1 lg) or pcDNA3.1(+)-TRIM11-Myc (0.1 lg), was transfec-
ted into 293EBNA cells in 3.5-cm dishes, and expressed for 36 h.
The cultured cells were incubated further with or without 10 lM
MG132 for 12 h. Collected cells were lysed in RIPA Buﬀer (50 mM
Tris–HCl, pH 8.0, 150 mM NaCl, containing 0.1% SDS, 1.0% deoxy-
cholate, 0.5% IGEPAL-CA630, and protease inhibitors; 0.1 mM
PMSF, 2 lg/ml aprotinin, 2 lg/ml leupeptin and 2 lg/ml pepstatin)
and incubated on ice for 30 min. Cell lysates were cleared by centrifu-
gation at 15000 rpm for 30 min at 4 C and the supernatants were sub-
jected to FLAG pull-down analysis.
2.12. Reporter assay for TGFb-ARC105 signaling pathway
A chimeric intron region containing Renilla Luciferase fragment was
excised from pRL-TK vector (Promega) with HindIII and BamHI and
ligated into the HindIII and BamHI sites of pcDNA3.1(+) to construct
CMV promoter driven internal control vector, pcDNA3.1(+)-Chi-
m.Int.-RL. 293EBNA cells were plated in 24 wells plate, and cultured
until cell density became 80–90%. At these points, a plasmid mixture of
p3TP-Lux vector as a TGF-b speciﬁc reporter plasmid [24],
pcDNA3.1(+)-Chim.Int.-RL as an internal control plasmid and a mix-
ture of pcDNA3.1(+)-ARC105-FLAG, pcDNA3.1(+)-TRIM11-Myc
plasmid, and pcDNA3.1(+) empty vector in the ratio indicated in
Fig. 6 was transfected using Lipofectamine 2000 reagent (Invitrogen)
according to manufacturer’s protocol. The total amount of vector in
each experiment was adjusted to 0.626 lg. Ten hours after transfec-
tion; 40 ng/ml TGF-b1 in OPTI-MEM (Invitrogen) was added to each
well to the ﬁnal concentration of 5 ng/ml. After another 6 h incubation,
cells were harvested and luciferase activity was measured using Prome-
ga’s Dual Luciferase Assay Kit and luminometer (Lumicounter 700;
Microtech Nichi-on, Chiba, Japan).reproducibly observed in the pull-down assay. Molecular weight
markers are shown at left. (B) Pull-down analysis of ARC105-FLAG
with TRIM11-GFP in co-transfected cells. IP indicates that immuno-
precipitation of the indicated protein as aﬃnity bait was done. Protein
bands were detected by Western blotting with anti-FLAG (1:10000) or
anti-GFP (1:1000) antibody. +, plasmid containing a DNA fragment
encoding ARC105-FLAG, TRIM11-GFP, or GFP was transfected; ,
untransfected. Lanes 1 and 4; pcDNA3.1 vector without any insertion
was transfected (control). An aliquot of whole-cell extract (50 lg) was
loaded onto the WCE lanes 1–3. Molecular weight markers are shown
at left.3. Results
3.1. TRIM11 interacts with ARC105
To identify possible binding partners of TRIM11 in the cell,
we expressed FLAG-tagged TRIM11 (TRIM11-FLAG) in hu-
man embryonic kidney cells expressing the Epstein-Barr virus
nuclear antigen (293EBNA cells) and immunoprecipitated cell
lysates with anti-FLAG antibody. At least two protein bands
that were not TRIM11 corresponding to the molecular weights
of 90 kDa and 95 kDa on SDS–PAGE were reproducibly
found associated with TRIM11-FLAG in at least three inde-
pendent experiments (Fig. 1A). Peptide mass ﬁngerprint
(PMF) analysis identiﬁed the smaller band as ARC105 (mass
matched 14/25, sequence coverage 21%, mean error
3.59 ppm, data tolerance 14 ppm, accession no. gi14276857:
molecular weight 82325). ARC105 has been reported to showa doublet pattern in SDS–PAGE analysis [10]. The larger
95 kDa band may correspond to one of the doublet bands re-
ported. To further conﬁrm the physical association between
TRIM11 and ARC105, we co-transfected ARC105-FLAG
and TRIM11-GFP into 293EBNA cells, immunoprecipitated
the cell lysates with anti-FLAG antibody, and conﬁrmed that
the immunoprecipitate contained TRIM11-GFP (Fig. 1B);
thus, a reciprocal interaction was conﬁrmed.
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of the cell
We also examined the cellular localization of TRIM11 and
ARC105 to assess their speciﬁc association in vivo. When we
transfected either TRIM11-GFP or ARC105-FLAG into
293EBNA cells and performed immunocytochemical analysis,
we observed that TRIM11-GFP localized diﬀusely in the cyto-
plasm and the nucleoplasm as reported previously by Rey-
mond et al. ([5], Fig. 2A), whereas ARC105-FLAG localizedFig. 2. Cellular localization of TRIM11 and ARC105. (A) Localization of
position of the nuclei; TRIM11-GFP, corresponding immunolocalization of
DAPI. (B) Cellular localization of ARC105-FLAG. ARC105-FLAG, typica
Merge, merge of ARC105-FLAG and DAPI staining; DIC, a transmitted ima
expressed ARC105 in 293EBNA cells. ARC105: visualized image of native A
immunostaining of TRIM11-GFP and ARC105-FLAG in 293EBNA cells.
Nucleolar colocalization of TRIM11-GFP and ARC105-FLAG, scale bar in
after the transfection of the plasmid for expressing the protein indicated.predominantly in the nucleoplasm (Fig. 2B). We next exam-
ined the cellular localization of endogenous ARC105 with
anti-ARC105 antibody and conﬁrmed that endogenous
ARC105 also localizes predominantly in the nucleus
(Fig. 2C). Thus, the cellular localization of exogenously ex-
pressed FLAG-tagged ARC105 was indistinguishable from
that of native ARC105. When TRIM11-GFP and ARC105-
FLAG were co-transfected, we noted that they co-localized
in the nucleoplasm of most of the co-transfected cellsTRIM11-GFP in 293EBNA cells. DAPI, DAPI image showing the
exogenously expressed TRIM11; Merge, merge of TRIM11-GFP and
l immunostaining pattern of exogenously expressed ARC105-FLAG;
ge of transfected 293EBNA cells. (C) Immunostaining of endogenously
RC105. Merge: merge of endogenous ARC105 and DAPI. (D) Double
Merge, merged image of TRIM11-GFP and ARC105-FLAG. (E,F)
dicates 10 lm. All immunocytochemical observation was done at 24 h
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TRIM11 was localized mainly in the cytoplasm without co-
expression of ARC105 (Fig. 2A and D–F). We, therefore,
examined a possibility that the expression of ARC105 induced
re-location of TRIM11 from the cytoplasm to the nucleo-
plasm. We constructed the cells that expressed stably
TRIM11-GFP, conﬁrmed that almost 100% of the cells were
expressed TRIM11-GFP dominantly in the cytoplasm, and
found that more than 70% of the ARC105-HA expressing cells
showed the dominant nucleoplasmic localization of TRIM11-
GFP (supplementary Fig. 1A and 1B). These results strongly
suggest that the expression level of ARC105 regulates the
nucleoplasmic localization of TRIM11. In addition, we ob-
served that the two proteins co-localized in the nucleolus in less
than 5% of the co-transfected cell population (Fig. 2E and F).
These results suggest that the association between TRIM11
and ARC105 occur at least in the nucleoplasm and possibly
in the nucleolus under some physiological conditions, and im-
ply that ARC105 regulates the nucleoplasmic and/or nucleolar
localization of TRIM11 either through the ability of ARC105
to translocate TRIM11 from the cytoplasm to the nucleus or
to retain TRIM11 in the nucleoplasm.Fig. 3. Identiﬁcation of ARC105-associating domains in the TRIM11
molecule. (A) Schematic representation of the domains of the full-
length and truncated TRIM11 proteins. Hatched boxes represent the
RING ﬁnger, B-Box, coiled-coil, SPRY-associated and SPRY
domains, as indicated. The amino acid residue numbers of TRIM11
and the deletion mutants are shown to the right of the corresponding
constructs. A FLAG tag was added to the C-terminus of each peptide
(not indicated in the diagram). (B) Pull-down analysis of TRIM11
deletion mutants. Each of the deletion mutants was transfected into
HEK293 cells stably expressing ARC105-HA, and pulled down with
anti-FLAG antibody-conjugated beads. Western blotting was per-
formed with either anti-HA (1:10000) or anti-FLAG (1:10000)
antibody after SDS–PAGE separation of proteins associated with
FLAG-TRIM11 deletion mutants. The asterisks indicate TRIM11
deletion mutant proteins as determined by calculation of their
molecular weight. (C) Each of the deletion mutants was transfected
into 293EBNA cells and pulled down with anti-FLAG antibody-
conjugated beads. Western blotting was performed with either anti-
ARC105 (1:100) or anti-FLAG antibody after SDS–PAGE separation
of proteins associated with FLAG-TRIM11 deletion mutants. Aster-3.3. The coiled-coil and C-terminal domains of TRIM11 are
required for association with ARC105
We next examined which TRIM11 domains are responsible
for interacting with ARC105. Based on the domain structure
of TRIM11 (containing a RING ﬁnger, a B-Box, a coiled-coil
domain, a SPRY-associated and a SPRY domain), we ﬁrst
constructed ﬁve FLAG-fused domain mutants, TDN-R (87-
468), TDN-RB (128-468), TDN-RBCC (286-468), TDC-SP (1-
338) and TDC-SASP (1-285) (Fig. 3A) and expressed each of
these in HEK293 cells stably expressing HA-tagged ARC105
(ARC105-HA). Each of the immunoprecipitates prepared with
anti-FLAG-M2 beads was analyzed by Western blotting with
anti-FLAG and anti-HA antibodies (Fig. 3B). ARC105 was
found to be associated with two mutants, TDN-R (87-468)
and TDN-RB (128-468), but not with the other mutants. In
addition, we detected endogenous ARC105 in the immunopre-
cipitates obtained from the 293EBNA cells transfected with the
TDN-R (87-468) or TDN-RB (128-468) mutants by Western
blot analysis with anti-ARC105 antibody, thereby demonstrat-
ing that the two mutants also associate with endogenous
ARC105 (Fig. 3C). For safety in case that the inability of
the other truncated mutants, TDN-RBCC, TDC-SP, TDC-
SASP, to bind to ARC105 were due to the delocalization of
those mutants in the cell, we examined the cellular localization
of those mutants by immunocytochemical analysis and showed
that those truncated mutants localized in the nucleus as well as
the cytoplasm similarly to full-length TRIM11 (supplementary
Fig. 2). These results indicate that the coiled-coil, SPRY-asso-
ciated and SPRY domains are required for binding of
TRIM11 to ARC105, whereas the RING ﬁnger and B-Box do-
mains are not. The coiled-coil, SPRY-associated and SPRY
domains are also reported to interact with humanin [6].isks show TRIM11 deletion mutants as determined by calculation of
their molecular weight.3.4. TRIM11 destabilizes ARC105 probably through the
ubiquitin–proteasome degradation pathway
The RING ﬁnger domain is proposed to be a consensus do-
main for binding to ubiquitin conjugating enzymes [11];
accordingly, proteins containing a RING ﬁnger domain areconsidered to be ubiquitin ligase E3s [12–14]. In fact, some
TRIM family proteins interact with ubiquitin ligase E2 and
have proved to be E3 ubiquitin ligases [15–18]. Given the re-
Fig. 4. Destabilization of ARC105 by co-expression of TRIM11. (A)
Eﬀect of TRIM11 expression on ARC105 stability examined by an
immunoblot. Each of the antibodies used for immunoblot is indicated
next to the abbreviation IB. ARC105-HA was co-transfected with
pcDNA3.1(+)-empty vector (lanes 3 and 4), TRIM11-FLAG (lanes 5
and 6), or TDN-R-FLAG (TDN-R; lanes 7 and 8) with (+) or without
() MG132. Lanes 1 and 2 show whole-cell extracts of cells without
any expression vector. MG132 (10 lM) was added 24 h post
transfection (+) and incubated for 12 h. An aliquot of 100 lg of
whole-cell extract was loaded in each lane. Expression of GFP from
pEGFP-N1-GFP was used as a control for transfection. (B) Dose-
dependent eﬀect of TRIM11 on ARC105 stability. Expression vector
containing TRIM11-FLAG was mixed with pcDNA3.1(+)-empty
vector in the ratios indicated, and co-transfected with ARC105-HA
and GFP (as a transfection control). MG132 (10 lM) was added 24 h
post transfection (+) and incubated for 12 h. Western blotting was
performed with anti-HA, anti-FLAG, and anti-GFP antibodies as
indicated at the right. An aliquot of 50 lg of whole-cell extract was
loaded in each lane. (C) Dose-dependent eﬀect of TDN-R on ARC105
stability. Expression vector containing TDN-R was mixed with
pcDNA3.1(+)-empty vector in the ratios indicated, and co-transfected
with ARC105-HA and GFP. MG132 (10 lM) was added 24 h post
transfection (+) and incubated for 12 h. Western blotting was
performed with anti-HA (1:10000), anti-FLAG (1:10000), anti-GFP
(1:1000), and anti-tubulin (1:10000) antibodies as indicated at the
right.
H. Ishikawa et al. / FEBS Letters 580 (2006) 4784–4792 4789port that TRIM11 binds to and destabilizes humanin as a
probable E3 ubiquitin ligase [6], we investigated whether
TRIM11 destabilizes ARC105 through the ubiquitin–protea-
some degradation pathway. We ﬁrst examined whether co-
expression of TRIM11 destabilizes ARC105 and, if so,
whether the proteasome inhibitor MG132 inhibits the
TRIM11-induced ARC105 destabilization. Co-expression of
TRIM11-FLAG decreased the amount of ARC105; further-
more, MG132 treatment reversed the eﬀect of TRIM11 on
ARC105 levels (Fig. 4A). Current report showed that the
application of MG132 induces speciﬁc gene through CHOP
transcription factor, which binds a consensus sequence, 5 0-
GNGKATTGCNNYY-3 0 (ex. GAGGATTGCGATC) [19].
Although we did not ﬁnd such consensus sequence in the
expression vector with CMV promoter we used, we examined
a possibility that MG132 induced ARC105 gene expression
and caused the increase of ARC105 in our experiment. How-
ever, we did not detect any signiﬁcant increase of the expres-
sion of the ARC105 mRNA (supplementary Fig. 3). We also
examined the eﬀect of expression of TRIM11-GFP on the
ARC105-HA by immunocytochemical method, and found that
the staining intensity of ARC105-HA was certainly reduced in
the cells expressed TRIM11-GFP at higher level when com-
pared with in the cells expressed TRIM11-GFP at lower level
(supplementary Fig. 1B, indicated by arrows). Those results
suggest that proteasomal degradation of ARC105 is acceler-
ated by co-expression of TRIM11. Given that TRIM11 has
a RING ﬁnger domain and is a possible E3 ubiquitin ligase,
we also tested the possible involvement of the RING ﬁnger do-
main in destabilization of ARC105 by co-expressing ARC105
and a TRIM11 domain mutant lacking the RING ﬁnger do-
main (TDN-R). We found that expression of this mutant pre-
vented degradation of ARC105, and that MG132 had little
eﬀect on the stability of ARC105 in the TDN-R-transfected
cells (Fig. 4A, lanes 7 and 8). In addition, we transfected the
ARC105-HA plasmid with a mixture of pcDNA3.1 vector
and full-length TRIM11 plasmid or a mixture of pcDNA3.1
vector and the TDN-R deletion mutant plasmid to examine
dose dependent eﬀect of TRIM11 or TDN-R on degradation
of ARC105. We found that full-length TRIM11 dramatically
decreased expression of ARC105 (Fig. 4B). Although treat-
ment with MG132 could restore ARC105 expression at low
levels of full-length TRIM11 plasmid, it could not completely
restore ARC105 expression at higher doses (Fig. 4B). On the
other hand, the TDN-R mutant showed no eﬀect or somewhat
elevated ARC105-HA levels regardless of MG132 treatment
(Fig. 4C). We also observed very similar results for the domain
mutant TDN-RB that lacks the RING ﬁnger and B-Box
domains but is still able to interact with ARC105 (data not
shown). Furthermore, we examined the eﬀect of the other
truncated mutants, TDN-RBCC, TDC-SP, TDC-SASP, which
lack RING ﬁnger domain or had no binding activity to
ARC105 (Fig. 3), on the expression level of ARC105. Cer-
tainly, those mutants did not have any signiﬁcant eﬀect on
that (supplementary Fig. 4). These results indicate that the
RING ﬁnger domain and the ARC105-binding domains
are required for destabilizing ARC105. In order to examine
the eﬀect of TRIM11 expression on ubiquitination of
ARC105, we transfected HA-tagged ubiquitin (HA-Ub) in
addition to ARC105-FLAG and Myc-tagged TRIM11
(TRIM11-Myc) into 293EBNA cells, performed a pull-down
assay with FLAG antibody-conjugated beads and analyzedthe immunoprecipitates by Western blotting with anti-HA
antibody (Fig. 5). Poly-ubiquitination of ARC105-FLAG
was observed in all ARC105-transfected cells, regardless of
the expression of TRIM11-Myc (Fig. 5); however, the degree
Fig. 5. Eﬀect of TRIM11 expression on ARC105 ubiquitination. +*
indicates that pcDNA3.1(+)-empty vector was co-transfected to keep
constant the total amount of vector added to the cells. Pull-down
assays were performed with anti-FLAG antibody-conjugated beads
followed by Western blotting with the antibodies indicated. WCE;
aliquots of whole cell extract of 293EBNA cells were loaded on to
SDS–PAGE gel. GAPDH was used as a loading control. Western
blotting was performed with anti-HA (1:10000), anti-FLAG
(1:10000), anti-Myc (1:100), and anti-GAPDH (1:10000) antibodies
as indicated at the right.
Fig. 6. Eﬀect of TRIM11 expression on ARC105 function mediated by
TGFb signaling. Expression vector encoding ARC105-FLAG was
mixed with pcDNA3.1(+)-empty vector or with pcDNA 3.1(+)-
TRIM11-Myc plus pcDNA3.1(+)-empty vector, and adjusted the
total amount of the vectors to 0.5 lg. A mixture of reporter plasmid,
125 ng of p3TP-Lux plasmid (as TGFb reporter vector) and 1.25 ng of
pcDNA3.1 (+)-Chim.Int.-RL plasmid (as internal control vector) were
co-transfected with those. The values of relative luciferase activity
measured are normalized to those obtained from TGFb untreated
control. The vertical line within each histogram indicates the means
and standard deviations of the triplicated experiments. , untransfec-
ted or untreated; +, treated with TGFb. Western blotting was
performed with anti-FLAG (1:10000), anti-Myc (1:100), and anti-
GAPDH (1:10000) antibodies as indicated at the right.
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TRIM11-Myc and incubation with MG132 (Fig. 5). In addi-
tion, anti-FLAG antibody detected very weak bands corre-
sponding to some poly-ubiquitinated forms of ARC105 in
the TRIM11-Myc-expressing cells (Fig. 5). These results sug-
gest that TRIM11 destabilizes ARC105 through the ubiqui-
tin–proteasome degradation pathway.
We noted that there was a band, whose size was a little bit
higher than that of ARC105-FLAG in ARC105-untransfected
samples (Fig. 5, lanes 1 and 2). This band was also observed in
the ARC105-transfected samples when the amounts of the
loading samples for SDS–PAGE are reduced (supplementary
Fig. 5). We have identiﬁed the protein corresponding to this
band as kinesin-like spindle protein (HKSP) by mass-based
analysis after in-gel-protease digestion (data not shown). This
undesired association of HKSP protein and several other pro-
teins with FLAG-antibody had been observed when the anti-
FLAG antibody beads were used for immunoisolation [8,20].
The extent of the association varied depending on the lots of
the anti-FLAG antibodies purchased because of unknown rea-
son; we had reported this problem previously [20]. Because the
size of HKSP is very similar to ARC105, the HKSP and
ARC105 bands overlapped each other in the ARC105-trans-
fected samples shown in Fig. 5.3.5. TRIM11 suppresses ARC105 mediated transcriptional
activation induced with TGFb
Given the fact that ARC105 has a role in linking TGFb/
Activin/Nodal/Smad2/3 signaling to ARC complex-dependent
transcription [24], we next examined the eﬀect of TRIM11 on
TGFb-induced ARC105-dependent transcription by usingconventional reporter assay. Using p3TP-Lux reporter plas-
mid, we conﬁrmed that the transcriptional activity was in-
creased in proportion to the amount of the ARC105
expression vector cotransfected under TGFb stimulation
(Fig. 6, lanes 1–4, supplementary Fig. 6). On the other hand,
the expression of TRIM11 reduced the eﬀect of ARC105 on
the TGFb-induced transcriptional activity in a dose-dependent
manner (Fig. 6, lanes 5 and 6). We also examined the expres-
sion levels of ARC105 and TRIM11, and showed that they
were consistent with the luciferase activities obtained by using
reporter assay (Fig. 6, upper inset). These results suggest
strongly that TRIM11 regulates ARC105 function induced
by TGFb signaling through ubiquitin–proteasome pathway,
though we cannot exclude a possibility at present that
TRIM11 may have the targeted degradation activity on the ex-
pressed luciferase itself.
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In this study, we showed that TRIM11 interacts with
ARC105 through a region containing a coiled-coil, a SPRY-
associated domain and a SPRY domain and causes the desta-
bilization of ARC105 through the RING ﬁnger domain. Deg-
radation of ARC105 was suppressed by treatment with the
proteasome inhibitor MG132. In addition, we demonstrated
that truncated mutants of TRIM11 lacking the RING ﬁnger
domain stabilized ARC105, and that poly-ubiquitination of
ARC105 increased upon expression of TRIM11. Given the
fact that the RING ﬁnger domain of TRIM11 is required for
ARC105 destabilization and that TRIM11 is likely an ubiqui-
tin ligase E3 [6], these results suggest that the function of
ARC105 is regulated by TRIM11 through the ubiquitin–pro-
teasome degradation pathway.
ARC105 was identiﬁed initially as a phorbol ester 12-O-tet-
radecanoylphorbol-13-acetate (TPA)-inducible gene-1 product
(TIG1) in the human leukemia K562 cell line [21]. It is also
known as positive cofactor 2 glutamine/Q-rich-associated pro-
tein (PC2) [10]. ARC105 is a component of the ARC complex
that mediates chromatin-directed transcription activation, and
has roles in basal transcription [22,23]. A recent report showed
that ARC105 stimulates Activin/Nodal/Smad2 signaling in
Xenopus laevis embryos, inducing axis duplication and
mesoendoderm diﬀerentiation, and enhances TGFb and Acti-
vin response in human cells; thus, ARC105 links TGFb/Acti-
vin/Nodal/Smad2/3 signaling to ARC complex-dependent
transcription [24]. Because TRIM11 suppresses the ARC105-
dependent transcriptional activity induced by TGFb in the
conventional reporter assay we used (Fig. 6), it is strongly sug-
gested that TRIM11 is involved in a process that links TGFb/
Activin/Nodal/Smad2/3 signaling to ARC complex-dependent
transcription. Our present results also suggest that this process
is the ubiquitination of ARC105 speciﬁcally targeted by
TRIM11, leading to the proteasome-dependent degradation.
Given the result that the increase of ARC105 expression in-
duced the translocation of TRIM11 from the cytoplasm to
the nucleus, it is likely that the proteasome-dependent degra-
dation of ARC105 occurs in the nucleoplasm. At present there
are two possibilities in which cellular compartment the interac-
tion of TRIM11 with ARC105 takes place ﬁrst; one is that
takes place in the cytoplasm and another is in the nucleoplasm.
In the former case, the interaction of the two proteins leads to
the translocation from the cytoplasm to the nucleoplasm, but
will not cause the ubiquitination or poly-ubiquitination of
ARC105 at this process. Since the binding domain of TRIM11
to ARC105 is diﬀerent from that of ubiquitin ligase, the inter-
action between the two proteins may be regulated indepen-
dently of the ubiquitination of ARC105 with TRIM11. The
ability of TRIM11 to form homo-oligomer may be related to
this function. If this is the case, ARC105 may regulate ARC
complex-dependent transcription as a complex with TRIM11.
It is very intriguing to speculate that TRIM11 dissociates the
transcriptional machinery working on a gene after the termina-
tion of the transcription through the ubiquitin–proteasome
dependent degradation of ARC105. On the other hand, if
the interaction of TRIM11 takes place in the nucleoplasm after
translocation of ARC105, ARC105 may functions as a nucle-
oplasmic anchor of TRIM11. The increase of ARC105 expres-
sion will cause the increase of the presence of ARC105 in the
nucleoplasm, leading to the accumulation of TRIM11 in thenucleoplasm through the interaction with the ARC105. A sim-
ple scenario of this is that TRIM11 can shuttle between the
cytoplasm and the nucleoplasm. In either case, our results sug-
gest the presence of unknown regulatory mechanism by which
TRIM11 regulates a process that leads TGFb/Activin/Nodal/
Smad2/3 signaling to ARC complex-dependent transcription.
Certainly, further investigation of those possibilities will open
up new insights for the function of TRIM11 as well as the reg-
ulatory roles of ARC105 in ARC complex dependent tran-
scription.
TRIM11 also interacts with humanin, a neuroprotective
peptide that speciﬁcally suppresses Alzheimer’s disease-related
neurotoxicity, and TRIM11 is proposed to help regulate intra-
cellular levels of humanin through ubiquitin-mediated protein
degradation in neural tissues [6]. Our result coupled with this
report establishes that TRIM11 is the E3 ubiquitin ligase,
and that ARC105 is the second substrate for this enzyme iden-
tiﬁed to date, though we do not know the functional relevance
between those substrates in their physiological roles. In conclu-
sion, the present study deﬁnes a unique function of TRIM11 in
the TGFb signaling pathway linking to ARC complex-depen-
dent transcription.
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